Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 20:156:20-25.
doi: 10.1016/j.freeradbiomed.2020.05.023. Epub 2020 Jun 6.

The latency of peroxisomal catalase in terms of effectiveness factor for pancreatic and glioblastoma cancer cell lines in the presence of high concentrations of H2O2: Implications for the use of pharmacological ascorbate in cancer therapy

Affiliations

The latency of peroxisomal catalase in terms of effectiveness factor for pancreatic and glioblastoma cancer cell lines in the presence of high concentrations of H2O2: Implications for the use of pharmacological ascorbate in cancer therapy

Dieanira T Erudaitius et al. Free Radic Biol Med. .

Abstract

Previous research has identified variation in cancer cell line response to high levels of extracellular H2O2 (eH2O2) exposure. This directly contributes to our understanding cellular efficacy of pharmacological ascorbate (P-AscH-) therapy. Here we investigate the factors contributing to latency of peroxisomal catalase of a cell and the importance of latency in evaluating cell exposure to eH2O2. First, we develop a mathematical framework for the latency of catalase in terms of an effectiveness factor, ηeff, to describe the catalase activity in the presence of high levels of eH2O2. A simplified relationship emerges, [Formula: see text] when mprp/Dij≪1, where mp,rp, and [Formula: see text] are the experimentally determined peroxisome permeability, average peroxisome radius, and the pseudo first-order reaction rate constant, respectively. [Formula: see text] is the catalase concentration in the peroxisome and k2=1.7x107M-1s-1. Next, previously published parameters are used to determine the latency effect of the cell lines: normal pancreatic cells (H6c7), pancreatic cancer cells (MIA PaCa-2), and glioblastoma cells (LN-229, T98G, and U-87), all which vary in their susceptibility to exposure to high eH2O2. The results show that effectiveness is not significantly different except for the most susceptible, MIA PaCa-2 cell line, which is higher when compared to all other cell lines. This result is counterintuitive and further implies that latency, as a single parameter, is ineffective in forecasting cell line susceptibility to P-AscH- therapy equivalent eH2O. Thus, further research remains necessary to identify why cancer cells vary in susceptibility to P-AscH- therapy.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.. The latency of the catalase in the peroxisome is associated with the peroxisome membrane permeability, mp, and the overall average catalase activity within the peroxisome.
With respect to the overall activity, each catalase molecule in solution, represented on the left-hand side, has access to the same concentration of H2O2 in the well-mixed system. However, within the peroxisome (right), the catalase near the surface of the organelle will encounter higher concentration of H2O2 than the catalase near the center. This is depicted by the larger H2O2 arrow in the outer dashed surface compared to the smaller arrow for the inner dashed line. Since the overall reaction rate is a linear function of the concentration of H2O2, the reaction rate of the catalase near the center is reduced. The effectiveness factor takes this into consideration and directly correlates with observed latency.
Fig 2.
Fig 2.. The relationship of the effectiveness factor in terms of cellular properties expressed in terms of the Biot number, Bip, and the Thiele modulus, ϕp.
The Biot number is a function of peroxisome radius, rp, and peroxisome membrane permeability, mp. The Thiele modulus is a function rp of and catalase concentration, Ccatp. All cases have Bip ≪ 1 indicating that mass transfer resistance is highly significant, and, for a given Thiele modulus, increasing Bip increases effectiveness. Smaller ϕp result in higher effectiveness.
Fig 3.
Fig 3.. Comparison of the calculated effectiveness to cell lines used in ascorbate dosing studies.
These results demonstrate a trend; however, only the effectiveness between the highly susceptible MIA PaCa-2 and the other cell lines are statistically different. This observed difference is counterintuitive to the expectation that increased latency (low effectiveness) could result in increased susceptibility. References for figure: *Chen et al. (2005)[21], **Chen et al. (2008)[22], ***Du et al. (2010)[1].

References

    1. Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010;16(2):509–20. Epub 2010/01/14. doi: 10.1158/1078-0432.CCR-09-1713. - DOI - PMC - PubMed
    1. Cullen JJ, Spitz DR, Buettner GR. Comment on “Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer,” i.e., all we are saying is, give C a chance. Free Radic Biol Med. 2011;50(12):1726–7. Epub 2011/04/05. doi: 10.1016/j.freeradbiomed.2011.03.030. - DOI - PMC - PubMed
    1. Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta. 2012;1826(2):443–57. Epub 2012/06/26. doi: 10.1016/j.bbcan.2012.06.003. - DOI - PMC - PubMed
    1. Moser JC, Rawal M, Wagner BA, Du J, Cullen JJ, Buettner GR. Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer. Redox Biol. 2013;2:22–7. Epub 2014/01/08. doi: 10.1016/j.redox.2013.11.005. - DOI - PMC - PubMed
    1. Rawal M, Schroeder SR, Wagner BA, Cushing CM, Welsh JL, Button AM, et al. Manganoporphyrins increase ascorbate-induced cytotoxicity by enhancing H2O2 generation. Cancer Res. 2013;73(16):5232–41. Epub 2013/06/15. doi: 10.1158/0008-5472.CAN-13-0470. - DOI - PMC - PubMed

Publication types